BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9435927)

  • 21. Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation.
    Vu T; Ellard S; Speers CH; Taylor SC; de Lemos ML; Hu F; Kuik K; Olivotto IA
    Ann Oncol; 2008 Mar; 19(3):461-4. PubMed ID: 18006892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
    Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ
    J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The taxoids. Comparative clinical pharmacology and therapeutic potential.
    Eisenhauer EA; Vermorken JB
    Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa.
    Alshreef A; MacQuilkan K; Dawkins B; Riddin J; Ward S; Meads D; Taylor M; Dixon S; Culyer AJ; Ruiz F; Chalkidou K; Edoka I
    Value Health Reg Issues; 2019 Sep; 19():65-74. PubMed ID: 31096179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine plus docetaxel combination therapy.
    Verma S; Maraninchi D; O'Shaughnessy J; Jamieson C; Jones S; Martín M; McKendrick J; Miles D; Twelves C; Hornberger J
    Cancer; 2005 Jun; 103(12):2455-65. PubMed ID: 15892043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of sequential paclitaxel adjuvant chemotherapy for patients with node positive primary breast cancer.
    Limwattananon S; Limwattananon C; Maoleekulpairoj S; Soparatanapaisal N
    J Med Assoc Thai; 2006 May; 89(5):690-8. PubMed ID: 16756057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
    Hong WK
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):9-15. PubMed ID: 12108903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Taxoids: effective agents in anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
    Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
    Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Docetaxel therapy against anthracycline resistant breast cancer].
    Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y; Suzuma T; Tanino H
    Gan To Kagaku Ryoho; 1999 May; 26(6):781-8. PubMed ID: 10410147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
    Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of patients resistant to paclitaxel therapy.
    Valero V
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():17-9. PubMed ID: 8862705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of docetaxel for breast cancer.
    Lwin Z; Leighl N
    Expert Opin Pharmacother; 2009 Feb; 10(2):283-90. PubMed ID: 19236199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.